<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564989</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 2044</org_study_id>
    <nct_id>NCT04564989</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC</brief_title>
  <official_title>LCCC 2044: Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can&#xD;
      be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements&#xD;
      of circulating HPV DNA in blood plasma. The study will also investigate whether HPV&#xD;
      integration is associated with TRAF3 and CYLD mutations, and whether recurrence prediction&#xD;
      improves when looking at HPV integration along with TRAF3 and CYLD mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of OPSCC</measure>
    <time_frame>From date of therapy completion until biopsy-proven recurrence, assessed up to 5 years</time_frame>
    <description>Patients will undergo post-treatment CT scans per institutional standard of care to detect cancer recurrence. Status of recurrence of OPSCC will be confirmed based on biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From beginning or end of treatment until date of CT-detected recurrence or date of death, assessed up to 5 years</time_frame>
    <description>Time-to-recurrence will be defined as time lapsed from end (or start) of treatment to first date recurrence (biopsy proven occur later) is detected by CT scans, or death. Otherwise, time-to-recurrence is censored at end of study date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Value</measure>
    <time_frame>Baseline to up to 5 years</time_frame>
    <description>Positive Predictive Value (PPV) is defined as probability that patients with two consecutive positive cHPVDNA (i.e., detectable cHPVDNA) really develop OPSCC recurrence during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Predictive Value</measure>
    <time_frame>Baseline to up to 5 years</time_frame>
    <description>Negative Predictive Value (NPV) is defined as probability that patients without two consecutive positive cHPVDNA do not develop OPSCC recurrence during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life questionnaire</measure>
    <time_frame>Baseline until recurrence or up to 5 years</time_frame>
    <description>At specified timepoints before, during, and after treatment, patients will complete a questionnaire comprised of questions from the European Organization for Research and Treatment of Cancer (EORTC) QLQ H&amp;N35, which is for head and neck cancer patients, and EORTC QLQ C30, which is a general cancer assessment.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Oropharynx Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>HPV+ OPSCC Patients</arm_group_label>
    <description>Patients with p16+ squamous cell carcinoma of the oropharynx (or unknown primary) who will receive definitive cancer treatment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HPV+ oropharyngeal squamous cell carcinoma who will receive definitive cancer&#xD;
        treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  T0-T2 N2a-N3 M0 or T3-T4 N0-N3 M0 (AJCC 7th edition)&#xD;
&#xD;
          -  Biopsy proven squamous cell carcinoma of the oropharynx or unknown primary&#xD;
&#xD;
          -  No prior therapy&#xD;
&#xD;
          -  No evidence of distant metastatic disease&#xD;
&#xD;
          -  p16 positive = diffuse ≥ 70% tumor cell expression, with at least moderate (2/3+)&#xD;
             staining intensity&#xD;
&#xD;
          -  Planned for receipt of definitive cancer treatment&#xD;
&#xD;
          -  ECOG Performance Status 0-1&#xD;
&#xD;
          -  Patients must be deemed able to comply with the treatment plan and follow-up schedule.&#xD;
&#xD;
          -  Patients must provide study specific informed consent prior to study entry&#xD;
&#xD;
        Exclusion Criteria: All subjects meeting any of the exclusion criteria at baseline will be&#xD;
        excluded from study participation:&#xD;
&#xD;
          -  Prior history of radiation therapy to the head and neck&#xD;
&#xD;
          -  Prior history of head and neck cancer.&#xD;
&#xD;
          -  Inadequate pre-treatment tissue sample for tumor genomic analyses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendell Yarbrough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Hilliard</last_name>
    <phone>919-966-4432</phone>
    <email>chris_hilliard@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendell Yarbrough, MD</last_name>
    <phone>919-843-7091</phone>
    <email>dell@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Ma, MD</last_name>
      <phone>507-284-8227</phone>
      <email>ma.daniel@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Hilliard</last_name>
      <phone>919-966-4432</phone>
      <email>chris_hilliard@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Wendell Yarbrough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Papillomavirus</keyword>
  <keyword>HPV</keyword>
  <keyword>p16</keyword>
  <keyword>Oropharynx</keyword>
  <keyword>OPSCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

